CLINICAL_TRIALS
trial_result
· 2025-11-06
Clinical Trial Update: A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg [Phase 1]
Summary
Phase 1 dose-calibration study comparing IkT-001Pro to imatinib 400 mg in chronic myeloid leukemia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Inhibikase Therapeutics | Conditions: CML | Phase 1 | Status: COMPLETED